Alpha-MSH (α-Melanocyte-Stimulating Hormone)

PT-141/Bremelanotide Clinical Trials (RECONNECT Studies)

Kingsberg et al. (2019) reported results from the two pivotal RECONNECT Phase III trials (Studies 301 and 302) enrolling 1,247 premenopausal women with generalized acquired HSDD. Patients self-administered bremelanotide 1.75 mg SC as needed before anticipated sexual activity for 24 weeks. Bremelanotide significantly increased the number of satisfying sexual events (SSE) per month (mean increase 1.0 vs placebo, p<0.001) and reduced Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) scores. Approximately 25% of bremelanotide patients achieved clinically meaningful improvement versus 17% for placebo. These results supported FDA approval of Vyleesi in June 2019.

Melanocortin-Oxytocin Pathway

The MC4R-oxytocin axis is the primary efferent pathway mediating melanocortin pro-sexual effects. Argiolas & Melis (2013) demonstrated that oxytocin antagonists administered intracerebroventricularly or into the ventral subiculum of the hippocampus completely blocked alpha-MSH and bremelanotide-induced erections in rats, confirming oxytocin as an essential downstream mediator. PVN oxytocinergic neurons project to the spinal cord (lumbosacral autonomic centers) and to limbic areas (VTA, amygdala), providing both autonomic (pro-erectile) and motivational (pro-desire) output.

Comparison with PDE5 Inhibitors

The fundamental distinction is mechanism site: melanocortin agonists are central (brain), PDE5 inhibitors are peripheral (penis). This has several clinical implications:

1. Desire vs arousal: Melanocortins enhance desire and motivation; PDE5 inhibitors enhance the erectile response to existing desire
2. Female efficacy: PDE5 inhibitors have consistently failed in female sexual dysfunction trials because female arousal disorder is primarily central. Bremelanotide succeeded because it targets central mechanisms
3. PDE5i non-responders: Approximately 30–40% of ED patients fail PDE5 inhibitors. Diamond et al. (2004) showed bremelanotide efficacy in this population, including diabetic and post-prostatectomy patients
4. Combination potential: Because the mechanisms are non-overlapping, there is theoretical rationale for combining melanocortin agonists (central desire) with PDE5 inhibitors (peripheral erection), though this has not been studied in formal trials

Neuroprotection

Catania et al. (2010)) reviewed neuroprotective effects of alpha-MSH in models of cerebral ischemia, traumatic brain injury, and neuroinflammation. Alpha-MSH reduces brain inflammation through MC1R and MC4R on microglia and astrocytes, suppressing reactive gliosis and reducing infarct volume in stroke models. The peptide also attenuates blood-brain barrier disruption and reduces edema formation following CNS injury.

Immunomodulation

Luger et al. (2003) demonstrated that alpha-MSH modulates adaptive immunity by influencing dendritic cell maturation and T-cell polarization. MC1R signaling in dendritic cells promotes regulatory T-cell (Treg) differentiation and suppresses Th1/Th17 responses, suggesting a role in maintaining immune tolerance. This has implications for autoimmune diseases and transplant rejection.

Sexual Function

Alpha-MSH, through MC3R and MC4R in hypothalamic and limbic structures, modulates sexual arousal and erectile function. Argiolas & Melis (2013) established that alpha-MSH activates oxytocinergic neurons in the PVN, triggering oxytocin release that descends to sacral parasympathetic centers mediating genital arousal. This endogenous pathway is the basis for the pro-sexual effects of synthetic melanocortin agonists including PT-141/bremelanotide.

Appetite and Energy Homeostasis

The melanocortin theory of energy regulation, formalized by Cone (2005), established that alpha-MSH released from POMC neurons in the arcuate nucleus acts as the primary endogenous anorexigenic signal at MC4R in the paraventricular nucleus. This signaling is opposed by agouti-related peptide (AgRP), an endogenous MC4R inverse agonist released from adjacent NPY/AgRP neurons. The balance between alpha-MSH and AgRP tone at MC4R is the central integrator of peripheral energy signals (leptin, insulin, ghrelin) with central appetite regulation.

Loss-of-function mutations in MC4R are the most common monogenic cause of human obesity, affecting approximately 5% of severely obese individuals. POMC deficiency, which eliminates alpha-MSH production, causes severe early-onset obesity, adrenal insufficiency, and red hair pigmentation (Krude et al., 1998).

Pigmentation

Alpha-MSH is the primary physiological regulator of constitutive and facultative skin pigmentation. Upon UV exposure, keratinocytes upregulate POMC expression and secrete alpha-MSH in a paracrine fashion, stimulating neighboring melanocytes through MC1R. This UV-induced melanogenesis constitutes the tanning response. Slominski et al. (2005) demonstrated that the cutaneous melanocortin system operates as a local neuroendocrine circuit, with keratinocytes, melanocytes, and Langerhans cells all expressing components of the POMC/MC1R axis.

Genetic variants of MC1R that reduce alpha-MSH signaling (R151C, R160W, D294H) are associated with the red hair/fair skin phenotype, increased pheomelanin:eumelanin ratio, and elevated melanoma risk independent of UV exposure.

MC4R Knockout Models

MC4R knockout mice exhibit significant impairment in sexual behavior, including reduced mounting frequency, increased latency to intromission, and decreased ejaculation frequency in males, and reduced lordosis quotient in females. These phenotypes are independent of the obesity caused by MC4R loss, as pair-fed MC4R knockouts still show sexual deficits. Van der Ploeg et al. (2002) demonstrated that MC4R is both necessary and sufficient for melanocortin-induced sexual responses, as selective MC4R agonists reproduce the pro-sexual effects while MC3R-selective compounds do not produce erection in animal models.

Male vs Female Sexual Dysfunction

Bremelanotide has been studied in both male and female sexual dysfunction, with different clinical outcomes:

• Female HSDD: FDA-approved indication. The RECONNECT trials demonstrated efficacy for desire and distress endpoints in premenopausal women (Kingsberg et al., 2019)
• Male ED: Diamond et al. (2006) demonstrated intranasal bremelanotide efficacy in men with ED, including those who had failed sildenafil. RigiScan monitoring showed erections in 67% of subjects. However, the clinical program for male ED was not pursued to approval due to transient blood pressure elevations with the intranasal formulation and strategic focus on female HSDD
• Female arousal: Diamond et al. (2006) used vaginal photoplethysmography to confirm bremelanotide increased genital arousal (vaginal pulse amplitude) in women with FSAD during erotic stimulation

Anti-Inflammatory Signaling

Catania et al. (2004) conducted a comprehensive review establishing alpha-MSH as one of the most potent endogenous anti-inflammatory peptides. The anti-inflammatory mechanism operates through MC1R-dependent inhibition of NF-kappaB: alpha-MSH binding increases intracellular cAMP, which activates PKA-mediated phosphorylation of IkappaB, preventing NF-kappaB nuclear translocation and suppressing transcription of pro-inflammatory cytokines. This pathway has been demonstrated in macrophages, monocytes, neutrophils, dendritic cells, endothelial cells, and brain microglia.

Additional anti-inflammatory mechanisms include inhibition of neopterin and nitric oxide production, reduced expression of adhesion molecules (ICAM-1, VCAM-1) on endothelial cells, and suppression of chemokine production. These effects operate at picomolar to nanomolar concentrations, indicating high physiological potency.